We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...

Heron Therapeutics Inc (HRTX) stock saw a modest uptick, ending the day at $2.02 which represents a slight increase of $0.07 or 3.59% from the prior close of $1.95. The stock opened at $1.99 and ...

Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $36.41 which represents a slight increase of $2.07 or 6.03% from the prior close of $34.34. The stock opened at $35.06 and ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. Year to date, shares of ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced ...

Shares of Applied Therapeutics (NASDAQ: APLT) had skyrocketed 70.5% as of 10:43 a.m. ET on Wednesday. The huge gain came after the U.S. Food and Drug Administration (FDA) told the company that an ...